Skin cancer can be deadly, but most cases are not. The answer depends almost entirely on the type of skin cancer and how early it’s caught. Melanoma, the most dangerous form, kills an estimated 8,510 Americans per year, yet even melanoma has an overall five-year survival rate of about 95%. The less common types people rarely hear about, like Merkel cell carcinoma, are far more lethal. And the most common types, basal cell and squamous cell carcinoma, are almost never fatal when treated.
How Dangerous Each Type Is
There are several types of skin cancer, and they vary enormously in how life-threatening they are.
Basal cell carcinoma is the most common skin cancer by far. It grows slowly and almost never spreads to other parts of the body. Deaths from basal cell carcinoma are extremely rare, typically occurring only when tumors are ignored for years and invade deeper tissue. Most people have these removed in a quick outpatient procedure and never deal with them again.
Squamous cell carcinoma is the second most common type. It’s more aggressive than basal cell but still highly treatable. A small percentage of squamous cell cancers can spread to lymph nodes or distant organs, particularly in people with weakened immune systems or tumors in certain locations like the lips or ears. Even so, the vast majority are cured with early treatment.
Melanoma is responsible for the most skin cancer deaths despite being less common than the other two. An estimated 112,000 new cases will be diagnosed in the U.S. in 2026, with roughly 8,510 deaths. Melanoma is more likely to invade deeper layers of skin and spread through the bloodstream or lymphatic system. Its overall five-year survival rate is 94.7%, but that number masks a wide range depending on stage at diagnosis.
Merkel cell carcinoma is rare but significantly more lethal than melanoma. It has a five-year overall survival rate of just 60%, compared to 93% for melanoma. People diagnosed with Merkel cell carcinoma are roughly 2.3 times more likely to die from their cancer than those with melanoma. It’s uncommon enough that most people have never heard of it, but it’s worth knowing about, particularly for older adults and those with compromised immune systems.
Stage at Diagnosis Changes Everything
The single biggest factor in whether skin cancer is deadly is how far it has spread when it’s found. Using melanoma as the clearest example, the survival gap between early and late detection is dramatic.
When melanoma is caught while still localized to the skin where it started, the five-year survival rate is greater than 99%. That’s essentially the same life expectancy as someone without cancer. Once it spreads to nearby lymph nodes or surrounding tissue (regional stage), survival drops to 76%. And when melanoma reaches distant organs, both melanoma and Merkel cell carcinoma have five-year survival rates below 30%.
This pattern holds across skin cancer types. Cancers confined to the skin are almost always curable. Cancers that have traveled to internal organs are far harder to treat. The difference between those two scenarios often comes down to months of delay in getting a suspicious spot checked.
How Skin Cancer Becomes Fatal
Skin cancer doesn’t kill by staying on the skin. It becomes life-threatening when cancer cells enter the bloodstream or lymphatic system and establish new tumors in vital organs. For melanoma, the most common sites where this happens are other areas of skin and tissue just under it, followed by the lungs, liver, bones, and brain.
The lungs are the most common cause of death in metastatic melanoma, with tumors eventually causing respiratory failure. The brain is the second most common. Melanoma has an unusual tendency to spread to the central nervous system, and once it does, treatment becomes especially difficult because most therapies struggle to cross the blood-brain barrier effectively.
The liver is the most commonly affected internal organ overall. When cancer establishes itself in multiple organ systems simultaneously, the body’s ability to maintain normal function deteriorates.
Modern Treatment Has Improved Survival
For people diagnosed with advanced melanoma, the outlook has improved substantially over the past decade. Before newer immune-based treatments became available, advanced melanoma had a dismal prognosis. Now, drugs that help the immune system recognize and attack cancer cells have changed the trajectory for many patients.
Real-world data from the Netherlands tracking patients treated with these therapies from 2012 to 2019 showed a five-year survival rate of about 36% for advanced melanoma. That may not sound high, but it represents a dramatic improvement over the single-digit survival rates that were common before these treatments existed. Importantly, survival curves appear to plateau after several years, meaning a meaningful portion of patients who respond well to treatment may achieve long-term remission.
Why Some Groups Face Higher Risk
Skin cancer is most common in people with lighter skin, but that doesn’t mean others are safe. In fact, racial and ethnic minorities face worse outcomes when they do develop skin cancer. Black and Native American patients are twice as likely to be diagnosed at an advanced stage compared to white patients. Even when diagnosed at the same stage, Hispanic, Native American, Asian, and Black patients face a greater risk of dying.
Several factors drive this gap. Skin cancer in darker skin tones often appears in less obvious locations, like the palms, soles of the feet, or under fingernails, rather than in sun-exposed areas. These spots are easier to miss during self-checks and routine exams. Many people with darker skin also don’t consider themselves at risk, which delays the point at which they bring a concerning spot to a doctor’s attention.
Systemic barriers play a role too. Fewer dermatologists practice in communities with higher minority populations, and patients on Medicaid are more likely to be diagnosed at a later stage. Medical training has historically used clinical images showing skin conditions almost exclusively on lighter skin, which can lead to missed or delayed diagnoses by providers as well.
What Makes the Difference
The gap between a skin cancer that’s a minor inconvenience and one that’s life-threatening usually comes down to time. A melanoma caught at the localized stage has a survival rate above 99%. The same cancer caught after it has spread to lymph nodes drops to 76%. That difference represents the weeks or months between noticing a changing mole and actually getting it biopsied.
Paying attention to new or changing spots on your skin is the most effective thing you can do. The well-known ABCDE checklist (asymmetry, border irregularity, color variation, diameter larger than a pencil eraser, and evolving size or shape) remains a practical guide for melanoma. For non-melanoma types, watch for sores that don’t heal within a few weeks, raised growths with a central dip, or scaly red patches that persist. Any spot that bleeds, crusts over, and then bleeds again deserves a professional look.